27 March 2023
Biocept, Inc. a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary cerebrospinal fluid assay CNSide. This first patie The FORESEE trial is a multicenter, prospective clinical trial expected to enroll 40 patients with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM). The goal of the FORESEE trial
Read more...27 March 2023
Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful diagnosis. According to the American Cancer Society in 2022, the 5-year relative survival rate for localized breast cancer, cancer that has not spread outside the breast, is 99%, and for those whose cancer has spread outside the breast to nearby structures or lymph nodes, the survival rate is 86%. Over the last
Read more...ONO PHARMA USA, INC., announced that its candidate, tirabrutinib, a Bruton's tyrosine kinase inhibitor, was granted Orphan Drug Designation on March 21, 2023 by the U.S. Food and Drug Administration (FDA) for the treatment of patients with primary central nervous system lymphoma (PCNSL). The FDA's Orphan Drug Designation program supports the development and evaluation of investigational drugs and biologics that show promise for the diagnosis, treatment, or prevention of rare
Read more...Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces that it has developed a new reagent, Optimer®-Fc, for use in automated immunohistochemistry (IHC) workflows. Optimer-Fc tools consist of an Optimer binder conjugated to the Fc domain of an antibody. The Company has successfully demonstrated the functional integration of different Optimer binders into this conjugate format. This allows the broad target rang
Read more...Elegen, a leader in DNA innovation, today announced that it has successfully concluded its early access program and is now offering global commercial access to its new class of double-stranded DNA, developed to power the synthetic biology revolution. Elegen’s ENFINIA™ DNA represents a major advance in the field, offering an unprecedented combination of length, speed, and accuracy to streamline synthetic biology workflows and scale to meet the demands of the growing bioeconomy.
Read more...InvoX Pharma Limited a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited with an advancing pipeline of innovative products, today announces that F-star, an invoX company, has entered into a second licence agreement with Takeda for a novel next-generation immuno-oncology bispecific antibody. Under the terms of the licence agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing licence to research, develop, and commercialize a bispecific antibody
Read more...21 March 2023
Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class disease-modifying therapies for chronic age-related diseases, presented to key opinion leaders in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases. The data was presented during the 2023 American Academy of Dermatology (AAD) conference week, a gathering of the largest, most influential, and representative dermatology gro
Read more...With its uniqueness and creativity to deliver the best learning experience for its attendees, Eminence Business Media has yet again delivered one-of-a-kind programs to cater to the needs of the industry in the best possible way. The 3rd Annual GMP & Quality Management 2023 was designed with a unique approach of an amalgamating format of virtual and in-person conference for b
Read more...